Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | CTRC | Q99895 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427222 | 1.00 | PRSS1 (0.41) | PRSS1CTRCF2CYP19A1ELANE | |
| SCHEMBL7053913 | 1.00 | PRSS1 (0.41) | PRSS1CTRCF2CYP19A1ELANE | |
| SCHEMBL6427227 | 1.00 | PRSS1 (0.41) | PRSS1CTRCF2CYP19A1ELANE | |
| SCHEMBL9616924 | 0.81 | F2 (0.42) | PRSS1CTRCF2ELANECTSG | |
| SCHEMBL2845072 | 0.80 | PRSS1 (0.38) | PRSS1CTRCF2CYP19A1ELANE | |
| SCHEMBL14601491 | 0.79 | PRSS1 (0.37) | PRSS1CTRCF2ELANECTSG | |
| SCHEMBL14149503 | 0.74 | — | — | |
| SCHEMBL14113498 | 0.74 | — | — | |
| SCHEMBL16318869 | 0.74 | — | — | |
| SCHEMBL18239488 | 0.73 | MEN1 (0.36) | PRSS1CTRCF2CYP19A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897324-B2 | Process for the preparation of 11-oxaprostaglandins and intermediates therein | CHIROTECH TECHNOLOGY LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| US-20030166948-A1 | Process for the preparation of 11-oxaprostaglandins and intermediates therein | CHIROTECH TECHNOLOGY LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166948-A1 | Process for the preparation of 11-oxaprostaglandins and intermediates therein | CYP4A11, PTGER1, PTGIS | PRSS1 1347/4885CTRC 4264/4885F2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.